Allosteric MAPKAPK2 inhibitors improve plaque stability in advanced atherosclerosis.

Allosteric MAPKAPK2 inhibitors improve plaque stability in advanced atherosclerosis.

Atherosclerotic vascular disease resulting from unstable plaques is the leading cause of morbidity and mortality in subjects with type 2 diabetes (T2D), and thus a major therapeutic goal is to discover T2D drugs that can also promote atherosclerotic plaque stability. Genetic or pharmacologic inhibit...

Full description

Bibliographic Details
Main Authors: Lale Ozcan, Canan Kasikara, Arif Yurdagul, George Kuriakose, Brian Hubbard, Michael H Serrano-Wu, Ira Tabas
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2021-01-01
Series:PLoS ONE
Online Access:https://doi.org/10.1371/journal.pone.0246600

Similar Items

Similar Items